Hims & Hers Health, Inc. (NYSE: HIMS) reported Q3 EPS of $0.06, $0.04 worse than the analyst estimate of $0.10. Revenue for the quarter came in at $600 million versus the consensus estimate of $580.37 million.

GUIDANCE:

Hims & Hers Health, Inc. sees Q4 2025 revenue of $605-625 million, versus the consensus of $629.7 million.

• Financial Outlook
• Hims & Hers is providing the following guidance:
• For the fourth quarter 2025, we expect:
• Revenue of $605 million to $625 million.
• Adjusted EBITDA of $55 million to $65 million, reflecting an Adjusted EBITDA margin of 9% to 10%.
• For the full year 2025, we expect:
• Revenue of $2.335 billion to $2.355 billion.
• Adjusted EBITDA of $307 million to $317 million, reflecting an Adjusted EBITDA margin of 13%.
• For earnings history and earnings-related data on Hims & Hers Health, Inc. (HIMS) click here.